367 web-programmer-developer-"https:"-"UCL"-"CEA-Saclay"-"https:" positions at KINGS COLLEGE LONDON
Sort by
Refine Your Search
-
Listed
-
Category
-
Program
-
Field
-
programmes span pre-registration nursing and midwifery, and multidisciplinary post-graduate taught and research programmes. We are committed to staff development and offer opportunities to identify and access
-
, contracts and consultancy, oversees the administration of all internal faculty research funding and committee meetings and plays a key part in the development of the UoA 18 (Law) REF submission with support
-
Framework, 2021). King’s has played a major role in many of the advances that shape modern life, such as the discovery of the structure of DNA and research that led to the development of robots, radio
-
philanthropic opportunities. The Business Support Officer will also work closely with the People & Talent Manager, supporting in areas such as recruitment process, developing and organising training programmes
-
, commitment, and creativity of our people are at the heart of King’s success. The Talent team is responsible for developing a new strategy and setting up active talent management, including assessing and
-
the field of translational oncology research. Prof Van Hemelrijck also leads the Guy’s Cancer Real World Evidence (RWE) Programme with Dr Anne Rigg from Guy’s and St Thomas’ NHS Foundation Trust
-
Programmes Experience of working with supplier statement reconciliation Ability to work independently to meet tight deadlines Strong data entry skills; speed and accuracy Desirable criteria Experience
-
research programme, titled Collective Action for Race Equity in Health and Social Care (CARE-HSC), aims to address and dismantle structural factors that perpetuate racial discrimination and harassment within
-
About the role The Research Department of Biomedical Computing, within the School of Biomedical Engineering & Imaging Sciences, develops computational methods and AI technologies for automated
-
programmes in the UK with licensed and experimental CAR-T products being administered for patients with B-cell leukaemias, lymphomas, multiple myeloma, solid tumours and autoimmune disease. It has MHRA